Twenty Years of Progress Toward West Nile Virus Vaccine Development

Jaclyn A. Kaiser, Alan Barrett

Research output: Contribution to journalReview article

Abstract

Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.

Original languageEnglish (US)
JournalViruses
Volume11
Issue number9
DOIs
StatePublished - Sep 5 2019

Fingerprint

West Nile Virus Vaccines
Vaccines
West Nile virus
Attenuated Vaccines
Phase II Clinical Trials
North America
Culicidae
Disease Outbreaks
Immunity
Vaccination

Keywords

  • flavivirus
  • vaccine
  • West Nile virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Twenty Years of Progress Toward West Nile Virus Vaccine Development. / Kaiser, Jaclyn A.; Barrett, Alan.

In: Viruses, Vol. 11, No. 9, 05.09.2019.

Research output: Contribution to journalReview article

@article{ca169a35606a4d54a9376403c20367ae,
title = "Twenty Years of Progress Toward West Nile Virus Vaccine Development",
abstract = "Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.",
keywords = "flavivirus, vaccine, West Nile virus",
author = "Kaiser, {Jaclyn A.} and Alan Barrett",
year = "2019",
month = "9",
day = "5",
doi = "10.3390/v11090823",
language = "English (US)",
volume = "11",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Twenty Years of Progress Toward West Nile Virus Vaccine Development

AU - Kaiser, Jaclyn A.

AU - Barrett, Alan

PY - 2019/9/5

Y1 - 2019/9/5

N2 - Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.

AB - Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.

KW - flavivirus

KW - vaccine

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=85071966759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071966759&partnerID=8YFLogxK

U2 - 10.3390/v11090823

DO - 10.3390/v11090823

M3 - Review article

VL - 11

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 9

ER -